New perspectives on the overactive bladder: pharmacokinetics and bioavailability.

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Urology

Background:

• Overactive bladder (OAB) affects millions in the US, with oxybutynin historically being a primary treatment.
• Traditional oxybutynin therapy required multiple daily doses and caused significant adverse events like dry mouth and constipation.
• These drawbacks limited patient compliance and treatment effectiveness.

Purpose of the Study:

• To review the evolution of overactive bladder (OAB) treatments.
• To highlight the impact of controlled drug delivery systems on OAB medication pharmacokinetics.
• To discuss future directions in OAB pharmacotherapy and drug delivery.

Main Methods:

• Review of existing literature on overactive bladder (OAB) treatments.
• Analysis of pharmacokinetic alterations induced by controlled drug delivery systems.
• Exploration of emerging chemical entities and novel drug delivery technologies for OAB.

Main Results:

• Controlled drug delivery systems enhance antimuscarinic medication pharmacokinetics for OAB.
• Once-daily dosing and reduced adverse events are achievable with current advanced formulations.
• Improved efficacy and tolerability are key benefits of these new systems.

Conclusions:

• Controlled drug delivery significantly improves OAB treatment efficacy and patient experience.
• Future OAB treatments will likely involve new chemical entities and innovative delivery methods like transdermal patches and implants.
• These advancements promise more effective and convenient management of overactive bladder symptoms.